Vaxxinity (VAXX) Competitors $0.0005 +0.00 (+25.00%) As of 01/21/2025 02:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends VAXX vs. SMFL, BLPH, SEEL, NEXI, HSTO, SCPS, NAVB, EVLO, CMRA, and GNCAQShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Smart for Life (SMFL), Bellerophon Therapeutics (BLPH), Seelos Therapeutics (SEEL), NexImmune (NEXI), Histogen (HSTO), Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Smart for Life Bellerophon Therapeutics Seelos Therapeutics NexImmune Histogen Scopus BioPharma Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Vaxxinity (NASDAQ:VAXX) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment. Which has more risk & volatility, VAXX or SMFL? Vaxxinity has a beta of -17.72, suggesting that its stock price is 1,872% less volatile than the S&P 500. Comparatively, Smart for Life has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Do institutionals & insiders believe in VAXX or SMFL? 83.0% of Vaxxinity shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, VAXX or SMFL? Smart for Life has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.450.00Smart for Life$8.23M0.01-$22.68MN/AN/A Does the media prefer VAXX or SMFL? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment Vaxxinity Neutral Smart for Life Neutral Does the MarketBeat Community prefer VAXX or SMFL? Vaxxinity received 4 more outperform votes than Smart for Life when rated by MarketBeat users. However, 100.00% of users gave Smart for Life an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Smart for LifeOutperform Votes1100.00% Underperform VotesNo Votes Is VAXX or SMFL more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Smart for Life N/A N/A N/A SummarySmart for Life beats Vaxxinity on 4 of the 7 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63,000.00$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio0.0010.0188.8317.53Price / SalesN/A335.611,282.2680.28Price / CashN/A22.6336.6032.90Price / Book0.005.084.964.69Net Income-$56.93M$154.90M$117.89M$224.57M7 Day PerformanceN/A2.59%2.75%3.33%1 Month PerformanceN/A1.52%3.63%5.33%1 Year PerformanceN/A5.49%27.27%22.97% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00+25.0%N/A-99.9%$63,000.00N/A0.0090Gap DownSMFLSmart for LifeN/A$0.03+44.0%N/A-99.9%$204,000.00$11.11M0.00110Gap UpBLPHBellerophon Therapeutics0.3906 of 5 stars$0.01-25.5%N/A-80.5%$147,000.00$5.64M-0.0120Analyst ForecastNews CoverageGap DownSEELSeelos TherapeuticsN/A$0.39-4.3%N/A-100.0%$144,000.00$2.20M0.0020NEXINexImmuneN/A$0.10flatN/A-98.6%$140,000.00N/A-0.016Gap UpHSTOHistogenN/A$0.03flatN/A-92.6%$118,000.00$19,000.00-0.0120SCPSScopus BioPharmaN/A$0.00flatN/A-91.4%$13,000.00N/A0.009High Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastNews CoverageEVLOEvelo BiosciencesN/A$0.00flatN/A-99.1%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070 Related Companies and Tools Related Companies Smart for Life Competitors Bellerophon Therapeutics Competitors Seelos Therapeutics Competitors NexImmune Competitors Histogen Competitors Scopus BioPharma Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VAXX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
